查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363106

核酸药物CDMO市场规模、份额、趋势分析报告：按类型、服务、最终用户、用途、地区和细分市场预测，2023-2030年

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service (Process Development & Optimization, Manufacturing Services), By End-user, By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

核酸药物CDMO市场成长及趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球核酸药物CDMO市场规模将达到224.2亿美元，2023年至2030年年复合成长率为9.4%。

市场成长主要是由核酸药物需求增加、核酸技术进步以及 FDA 对核酸药物核准的增加等要素推动的，从而推动了对具有成本效益的合约开发和製造服务的需求。

生技公司、製药公司和学术机构对基因治疗研发的投资和兴趣不断增加，正在推动对 CDMO 服务的需求。 CDMO 在基因治疗製造中发挥重要作用。例如，作为 Sarepta Therapeutics 的商业製造合作伙伴，Catalent 在推进基因治疗解决方案方面发挥关键作用。

mRNA疫苗应对COVID-19大流行的成功展示了核酸医学的潜力，并刺激了该领域的进一步研究和投资。例如，赛诺菲在 2022 年 3 月宣布，将在未来年度内投入 10.2 亿美元（9.35 亿欧元）在法国开发信使 RNA 疫苗。赛诺菲将在 2026 年之前进行这项投资，作为 2021 年 6 月宣布的 20 亿欧元全球投资计画的一部分。这项倡议旨在进一步推进公司的 mRNA 策略。这种增资情境将促进市场成长。

此外，不断增加的 CDMO收购和合作预计将在未来年度加速核酸药物 CDMO 市场的成长。例如，2022 年 5 月，eureKARE 进行了价值 1.6098 亿美元（1.5 亿欧元）的合併，创建了一个细胞和基因治疗合约开发和製造组织 (CDMO)。

该公司成立了特殊目的收购公司 eureKING (SPAC)，以整合三个欧洲受託製造厂商(CDMO)。此外，FUJIFILM将于 2022 年 4 月透过收购加州 Atara Biotherapeutics, Inc. 的一家专门从事细胞治疗的製造设施，扩大其作为先进疗法合约开发和受託製造厂商(CDMO) 的产品组合。此类配合措施预计将促进市场成长。

核酸医药CDMO市场报告亮点

  • 2022 年，基于 RNA 的治疗领域占据了最大的收益占有率。基于 RNA 的疗法（主要是 mRNA）可用于治疗多种疾病。它们可以被设计为产生多种治疗性蛋白质，从而适用于不同的治疗领域。
  • 预计基因治疗领域的市场在未来年度将显着成长。这是因为基因治疗的临床成功正在帮助扩大其适应症。
  • 2022年，製造服务领域占据市场主导地位，占总收益占有率的38%以上。促进该领域成长的主要挑战包括复杂的製造流程、规模化和生产挑战以及成本效率。
  • 生技公司在2022年占据领先的收益占有率，超过58%，因为它们大力投资于创新治疗方法的研发。
  • 从用途来看，肿瘤学在 2022 年以超过 31.0% 的收益占有率引领全球市场。这是由于越来越多地采用基因疗法和基于 RNA 的疗法，以及用于肿瘤学的核酸药物的管道不断增加。
  • 2022年，北美在核酸治疗CDMO市场中占据最大收益占有率，达到38.49%。大量的投资和资金、强大的学术和研究机构以及 CDMO 不断扩大的全球影响力正在推动该地区的成长。

目录

第1章调查方法与范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场趋势及展望
  • 市场动态
  • 市场促进因素分析
  • 市场抑制因素分析
  • 营商环境分析
    • SWOT分析
    • 波特五力分析
  • COVID-19感染疾病的影响分析

第4章按类型分類的业务分析

  • 核酸药物CDMO市场：类型变异分析
  • 基因治疗
  • 基于RNA的治疗

第5章依服务分类的业务分析

  • 核酸医药CDMO市场：服务波动分析
  • 製程开发与最佳化
  • 製造服务
  • 分析和品管服务
  • 其他的

第6章最终使用者的业务分析

  • 核酸药物CDMO市场：终端用户波动分析
  • 製药公司
  • 政府及学术研究机构
  • 生技公司

第7章用途业务分析

  • 核酸药物CDMO市场：用途变异分析
  • 肿瘤学
  • 遗传疾病
  • 感染疾病
  • 其他的

第8章区域业务分析

  • 2022年及2030年按地区分類的核酸药物CDMO市场占有率
  • 北美洲
    • 2018-2030年北美核酸药物CDMO市场
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030年欧洲核酸药物CDMO市场
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 2018-2030年亚太核酸药物CDMO市场
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018-2030年拉丁美洲核酸药物CDMO市场
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • MEA核酸医药CDMO市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 公司分类
  • 策略规划
    • 併购
    • 合作
    • 新产品发布
  • 参与企业概况
    • Catalent
    • Thermo Fisher Scientific
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Cognate BioServices
    • Eurofins Genomics
    • Sirion Biotech
    • Oxford Biomedica
    • Danaher（Aldevron）
Product Code: GVR-4-68040-125-4

Nucleic Acid Therapeutics CDMO Market Growth & Trends:

The global nucleic acid therapeutics CDMO market size is expected to reach USD 22.42 billion by 2030, advancing at a CAGR of 9.4% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights:

  • The RNA-based therapies segment held the largest revenue share in 2022. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies
  • In 2022, the manufacturing services segment dominated the market, accounting for over 38% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency
  • The biotechnology companies held a major revenue share of over 58% in 2022 due to substantial investments in the research and development of innovative therapies
  • By application, the oncology segment led the global market with a revenue share of over 31.0% in 2022. This is attributed to the rising adoption of gene therapy and RNA-based therapeutics and the increasing pipeline of nucleic acid therapeutics for oncology
  • North America held the largest revenue share of 38.49% in the nucleic acid therapeutic CDMO market in 2022. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Driver Analysis
  • 3.6. Market Restraint Analysis
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
  • 4.2. Gene Therapy
    • 4.2.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
  • 4.3. RNA-based Therapies
    • 4.3.1. RNA-based Therapies Market, 2018 - 2030 (USD Billion)

Chapter 5. Service Business Analysis

  • 5.1. Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
  • 5.2. Process Development and Optimization
    • 5.2.1. Process Development and Optimization Market, 2018 - 2030 (USD Billion)
  • 5.3. Manufacturing Services
    • 5.3.1. Manufacturing Services Market, 2018 - 2030 (USD Billion)
  • 5.4. Analytical and Quality Control Services
    • 5.4.1. Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. End Users Business Analysis

  • 6.1. Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
  • 6.2. Pharmaceutical Companies
    • 6.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • 6.3. Government & Academic Research Institutes
    • 6.3.1. Government & Academic Research Institutes Market, 2018 - 2030 (USD Billion)
  • 6.4. Biotech Companies
    • 6.4.1. Biotech Companies Market, 2018 - 2030 (USD Billion)

Chapter 7. Application Business Analysis

  • 7.1. Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 7.3. Genetic Disorders
    • 7.3.1. Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Regional Business Analysis

  • 8.1. Nucleic Acid Therapeutics CDMO Market Share by Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Regulatory Framework
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Regulatory Framework
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.7. Sweden
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.8. Norway
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.9. Denmark
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.6. MEA
    • 8.6.1. MEA Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Mergers & Acquisitions
    • 9.2.2. Collaborations
    • 9.2.3. New Product Launches
  • 9.3. Participant's overview
    • 9.3.1. Catalent
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Lonza
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. FUJIFILM Diosynth Biotechnologies
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Cognate BioServices
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Eurofins Genomics
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Sirion Biotech
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Oxford Biomedica
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Danaher (Aldevron)
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of data sources
  • Table 2 Global Nucleic Acid Therapeutics CDMO Market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 4 Global Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 5 Global Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 6 Global Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 7 North America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 9 North America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 10 North America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 11 North America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 12 U.S. Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 14 U.S. Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 16 Canada Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 20 Europe Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 21 Europe Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 22 Europe Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 23 Europe Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 24 Europe Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 25 UK Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 26 UK Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 27 UK Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 28 UK Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 29 Germany Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 33 France Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 34 France Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 35 France Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 36 France Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 37 Italy Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Italy Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 39 Italy Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 40 Italy Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 41 Spain Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 42 Spain Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 43 Spain Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 44 Sapin Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 45 Denmark Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 46 Denmark Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 47 Denmark Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 48 Denmark Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 49 Sweden Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 50 Sweden Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 51 Sweden Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 52 Sweden Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 53 Norway Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Norway Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 55 Norway Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 56 Norway Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 57 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 58 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 59 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 60 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 61 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 62 Japan Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 63 Japan Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 64 Japan Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 65 Japan Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 66 China Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 67 China Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 68 China Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 69 China Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 70 India Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 71 India Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 72 India Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 73 India Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 74 South Korea Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 75 South Korea Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 76 South Korea Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 77 South Korea Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 78 Australia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Australia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 80 Australia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 81 Australia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 82 Thailand Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Thailand Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 84 Thailand Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 85 Thailand Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 86 Latin America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 87 Latin America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 88 Latin America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 89 Latin America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 90 Latin America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 91 Brazil Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 92 Brazil Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 93 Brazil Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 94 Brazil Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 95 Mexico Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 96 Mexico Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 97 Mexico Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 98 Mexico Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 99 Argentina Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 100 Argentina Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 101 Argentina Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 102 Argentina Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 103 MEA Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 104 MEA Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 105 MEA Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 106 MEA Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 107 MEA Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 108 South Africa Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 109 South Africa Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 110 South Africa Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 111 South Africa Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 112 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 116 UAE Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 117 UAE Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 118 UAE Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 119 UAE Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 120 Kuwait Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 124 Participant's overview
  • Table 125 Financial performance
  • Table 126 Type benchmarking
  • Table 127 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Nucleic Acid Therapeutics CDMO Market revenue, 2018-2030 (USD Billion)
  • Fig. 9 Nucleic Acid Therapeutics CDMO Market Snapshot
  • Fig. 10 Nucleic Acid Therapeutics CDMO Market driver impact
  • Fig. 11 Nucleic Acid Therapeutics CDMO Market Restraint Impact
  • Fig. 12 Porter's 5 Forces Analysis
  • Fig. 13 PESTEL Analysis
  • Fig. 14 Global Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
  • Fig. 15 Global Nucleic Acid Therapeutics CDMO Market: Type Key Takeaways
  • Fig. 16 Global Gene Therapy Market, 2018 - 2030 (USD Billion)
  • Fig. 17 Global RNA-based Therapies Market, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
  • Fig. 19 Global Nucleic Acid Therapeutics CDMO Market: Service Key Takeaways
  • Fig. 20 Global Process Development and Optimization Market, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Manufacturing Services Market, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Others Market, 2018 - 2030 (USD Billion)
  • Fig. 24 Global Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
  • Fig. 25 Global Nucleic Acid Therapeutics CDMO Market: End Users Key Takeaways
  • Fig. 26 Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • Fig. 27 Government & Academic Research Institute Market, 2018 - 2030 (USD Billion)
  • Fig. 28 Biotech Companies Market, 2018 - 2030 (USD Billion)
  • Fig. 29 Global Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
  • Fig. 30 Global Nucleic Acid Therapeutics CDMO Market: Application Key Takeaways
  • Fig. 31 Oncology Market, 2018 - 2030 (USD Billion)
  • Fig. 32 Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • Fig. 33 Infectious Diseases Market, 2018 - 2030 (USD Billion)
  • Fig. 34 Others Market, 2018 - 2030 (USD Billion)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 Regional Outlook, 2022 & 2030
  • Fig. 37 North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 38 U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 39 Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 40 Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 41 Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 42 UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 43 France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 45 Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 46 Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 47 Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 48 Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 49 Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 51 China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 52 India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 54 South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 55 Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 56 Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 57 Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 59 Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 60 Middle East and Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 61 South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 63 UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 65 Market participant categorization
  • Fig. 66 Heat map analysis